• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center
 

Core Facilities

Cancer Pharmacology

References

References

1.    Vrooman LM, Supko JG Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdiere C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB.  Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.  Ped Blood Cancer, 2010;54:199-205.  PMID: 19672973

2.    Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdière C, Michon B, Schorin M, Schwartz CL, O’Brien JE, Cohen HJ, Sallan SE.  Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.  Blood, 2010;115:1351-3.  PMID: 20007809; PMCID: PMC2826760

3.    Holdhoff M, Supko JG, Gallia GL, Hann CL, Bonekamp D, Ye X, Cao B, Olivi A, Grossman SA.  Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.  J Neurooncol, 2010;97:241-5.  PMID: 19768386 

4.    Phuphanich S, Supko JG, Carson KA, Grossman SA, Nabors LB, Mikkelsen T, Lesser G, Rosenfeld S, Desideri S, Olson JJ.  Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.  J Neurooncol, 2010;100:95-103.  PMID: 20213332 

5.    Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelson T, Fisher J, Desideri S, He X, Grossman SA.  A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.  J Neurooncol, 2010;100:261-8.  PMID: 20449631 

6.    Bird GH, Madani N, Perry AF, Princiotto AM, Supko JG, He X, Gavathiotis E, Sodroski JG, Walensky LD.  Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.  Proc Natl Acad Sci USA, 2010;107:14093-8.  PMID: 20660316; PMCID: PMC2922607 

7.    Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Simamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D.  Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells.  Mol Cancer Ther, 2011;10:806-16.  PMID: 21421804; PMCID: PMC3092019
 
8.    Chen T, Ozel D, Qiao Y, Harbinski F, Chen L, Denoyelle S, He X, Zvereva N, Supko JG, Chorev M, Halperin JA, Aktas BH.  Chemical genetics identify eIF2 kinase heme-regulated inhibitor as anticancer target.  Nat Chem Biol, 2011;7:610-6.  PMID: 21765405; PMCID: PMC3684262

9.    Nabors LB, Supko JG, Rosenfeld M, Chamberlain M, Phuphanich S, Batchelor T, Desideri S, Ye X, Wright J, Gujar S, Grossman SA.  Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.  Neuro Oncol, 2011;13:1324-30.  PMID: 21954442; PMCID: PMC3223097 

10.    Cedeno-Laurent F, Opperman MJ, Barthel SR, Hays D, Schatton T, Zhan Q, He X, Matta KL, Supko JG, Frank MH, Murphy GF, Dimitroff CJ.  Metabolic inhibition of galectin-1-binding carbohydrates accentuates antitumor immunity.  J Invest Dermatol, 2012;132:410-20.  PMID: 22158550; PMCID: PMC3258338 

11.    Yamada S, Kuroda T, Fuchs BC, He X, Supko JG, Schmitt A, McGinn CM, Lanuti M, Tanabe KK.  Oncolytic Herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation.  Cancer Gene Ther, 2012;19:160-70.  PMID: 22076044; PMCID: PMC3288710

12.    Grossman SA, Ye X, Peereboom D, Rosenfeld MR, Mikkelsen T, Supko JG, Desideri S.  Phase I study of terameprocol in patients with recurrent high-grade glioma.  Neuro Oncol, 2012;14:511-7.  PMID: 22323663; PMCID: PMC3309850

13.    Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ.  A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas.  Clin Cancer Res, 2012;18:3396-3406.  PMID: 22634319
 
14.    Goldberg SB, Supko JG, Neal JW, Muzikansky A, Digumarthy S, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Engelman JA, Lynch TJ, Sharma S, Settleman JE, Sequist LV.  A phase I study of erlotinib and hydroxychloroquine in advanced non-small cell lung cancer.  J Thor Oncol, 2012;7:1602-8.  PMID: 22878749 

15.    Chen L, Aktas BH, Wang Y, He X, Sahoo R, Zhang N, Denoyelle S, Kabha E, Yang H, Freedman RY, Supko JG, Chorev M, Wagner G, Halperin JA.  Tumor suppression by small molecule inhibitors of translation initiation.  Oncotarget, 2012;3:869-81.  PMID: 22935625; PMCID: PMC3478463 

16.    Hu J, Wen PY, Abrey LE, Fadul CE, Drappatz J, Salem N, Supko JG, Hochberg F.  A phase II trial of oral gimatecan for recurrent glioblastoma.  J Neurooncol, 2013;111:347-53.  PMID: 23232808 

17.    Peereboom DM, Ahluwalia MS, Ye X, Supko JG, Hilderbrand SL, Phuphanich S, Nabors LB, Rosenfeld MR, Mikkelsen T, Grossman SA.  NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.  Neuro Oncol, 2013;15:490-6.  PMID: 23328813; PMCID: PMC3607264
 
18.    Vrooman LM, Stevenson KE, Supko JG, O’Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study - Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.  J Clin Oncol, 2013;31:1202-10.  PMID: 23358966; PMCID: PMC3595424 

19.    Zhu AX, Ancukiewicz M, Supko JG, Sahani DV, Blaszkowsky LS, Meyerhardt JA, Abrams TA, McCleary NJ, Bhargava P, Muzikansky A, Sheehan S, Regan E, Vasudev E, Knowles M, Fuchs CS, Ryan DP, Jain RK, Duda DG.  Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study.  Clin Cancer Res, 2013;19:1557-66.  PMID: 23362324; PMCID: PMC3609423
 
20.    Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, Roberts JD, Grant S.  A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.  Clin Cancer Res, 2013;19:1873-83.  PMID: 23515411; PMCID: PMC3618599 

21.    Wolpin BM, Ng K, Zhu AX, Abrams T, Enzinger PC, McCleary NJ, Schrag D, Kwak EL, Allen JN, Bhargava P, Chan JA, Goessling W, Blaszkowsky LS, Supko JG, Elliot M, Sato K, Regan E, Meyerhardt JA, Fuchs CS.  Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) in patients with refractory, metastatic colorectal cancer.  Oncologist, 2013;18:377-8. 

22.    Brown JR, Messmer B, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, LaCasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS.  A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.  Haematologica, 2013;98:964-70.  PMID: 23545695; PMCID: PMC3669454

23.    Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.  Erwinia asparaginase achieves therapeutic activity following PEG-asparaginase allergy: a report from the Children’s Oncology Group.  Blood, 2013 Jun 5 [Epub].  PMID: 23741010